Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Re: Withdrawals from Pregabalin/Lyrica?

Posted by SLS on November 7, 2004, at 8:05:11

In reply to Withdrawals from Pregabalin/Lyrica?, posted by TheOutsider on November 7, 2004, at 7:52:40

Am J Psychiatry. 2003 Mar;160(3):533-40.

Pregabalin in generalized anxiety disorder: a placebo-controlled trial.

Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD,
Bielski RJ, Zimbroff DL, Davidson JR, Liu-Dumaw M.

Pfizer Global Research and Development, Ann Arbor Laboratories, MI, USA.

OBJECTIVE: Current drug therapies for generalized anxiety disorder have
limitations. In a controlled trial, the novel agent pregabalin was studied for
the treatment of patients with generalized anxiety disorder. METHOD: In this
double-blind study, patients with DSM-IV generalized anxiety disorder were
randomly assigned to receive pregabalin (150 mg/day or 600 mg/day), lorazepam (6
mg/day), or placebo. A 1-week placebo lead-in was followed by 4 weeks of
treatment and then a 1-week dose taper. The primary efficacy measure was the
Hamilton Anxiety Rating Scale score at endpoint. RESULTS: A total of 276
patients were randomly assigned to a treatment group and received at least one
dose of their assigned medication. Fewer patients given lorazepam (59%, N=40 of
68) completed the trial than did those given placebo (73%, N=50 of 69), 600
mg/day of pregabalin (71%, N=50 of 70), or 150 mg/day or pregabalin (90%, N=62
of 69). The mean baseline-to-endpoint decreases in total Hamilton anxiety scale
score in the patients given 150 mg/day of pregabalin (-9.2), 600 mg/day of
pregabalin (-10.3), and lorazepam (-12.0) were significantly greater than the
decrease in those given placebo (-6.8). As early as the week 1 observation,
pregabalin significantly reduced the total Hamilton anxiety scale score compared
with placebo. The most frequent adverse events reported for pregabalin and
lorazepam were somnolence and dizziness. There were no serious adverse events
reported by patients given pregabalin, and no withdrawal syndrome was associated
with pregabalin treatment. CONCLUSIONS: These results indicate that pregabalin
is an effective, rapidly acting, and safe treatment for generalized anxiety
disorder. In short-term treatment, pregabalin does not appear to have the
withdrawal symptoms associated with the benzodiazepines.

Publication Types:
Clinical Trial
Randomized Controlled Trial

PMID: 12611835 [PubMed - indexed for MEDLINE]

 

Thread

 

Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:SLS thread:412809
URL: http://www.dr-bob.org/babble/20041103/msgs/412815.html